Dr. Yina Hsing Huang's research lab focuses on understanding how certain immune cells, particularly tissue-resident memory T cells, can be sustained and made effective against cancer. The lab investigates innovative strategies for enhancing chimeric antigen receptor (CAR) T cell therapies, which show promise in treating solid tumors by overcoming the immune suppression created by the tumor environment. Their work aims to develop better long-lasting immune responses that can protect individuals from cancer recurrence.

Dr. Frances E. Lund's research lab focuses on understanding the memory B and T cells of the human immune system, particularly in the context of organ transplantation. They investigate how these cells evolve and persist over time, especially in tissues vital for transplant success. Their work aims to uncover insights that could lead to improved treatments for transplant patients by balancing protective and damaging immune responses.

Dr. Jordan S. Pober's lab at Yale University focuses on innovative approaches to improve organ transplantation and tissue engineering. By utilizing advanced techniques such as 3D printing and nanoparticle drug delivery, the lab aims to create human skin substitutes that enhance graft survival and reduce immune rejection. The research is highly relevant for developing better treatment options for patients requiring organ transplants.

Dr. Chaoran Li's lab at Emory University focuses on understanding how specialized immune cells called regulatory T cells (Tregs) function in the skin. These Tregs help prevent skin inflammation and maintain tissue health. The lab explores the metabolic processes and epigenetic changes that influence these immune cells, particularly in response to environmental factors. Their goal is to develop new therapeutic strategies to treat inflammatory skin diseases like psoriasis and atopic dermatitis.

Dr. Ziyin Li's lab at the University of Texas Health Science Center Houston focuses on understanding how a specific protozoan parasite, Trypanosoma brucei, divides and grows. This research is significant because it could lead to new treatments for human African Trypanosomiasis, a disease that currently has limited and toxic medications. By studying the unique process of cell division in this parasite, the lab aims to identify new drug targets that could help fight this serious disease.

Dr. Hubert M. Tse's lab focuses on improving islet transplantation for type 1 diabetes treatment by exploring innovative encapsulation methods. They aim to create a protective environment for pancreatic cells to prevent immune rejection, using a special coating that modulates immune responses. This research could lead to better outcomes for patients receiving islet transplants.

Dr. Murugesan Rajaram's lab at Ohio State University is focused on understanding how Mycobacterium tuberculosis (M.tb) interacts with the immune system, specifically macrophages, to survive and resist treatment. The lab aims to develop new therapies to combat tuberculosis by targeting the mechanisms that allow M.tb to evade the immune response. By studying the role of protein MDR1 and the host's innate immune response, the lab seeks to shorten treatment times and reduce drug resistance in TB.

Dr. Dirk Schnappinger's lab at Weill Medical College focuses on understanding tuberculosis (TB), a major global health issue. The lab investigates the mechanisms of new antibiotics called nitroimidazoles, which are essential for treating drug-resistant TB. By studying the genetics and metabolism of the TB bacteria, the team aims to enhance treatment strategies and develop more effective drugs.

Dr. Sabine Ehrt's lab focuses on understanding the role of M. tuberculosis (Mtb) and its metabolism during infection to aid in developing new tuberculosis drugs. The research particularly examines how different environments within the human body affect Mtb's survival and growth, especially regarding its carbon source requirements. By studying drug targets in animal models that mirror human conditions, her lab aims to find innovative therapeutic approaches to combat tuberculosis, a significant global health threat.

Dr. Brian Vanderven's lab at Cornell University focuses on developing new treatments for tuberculosis (TB) by targeting the bacterial mechanisms that allow TB to persist in the body. The lab is researching compounds that can stimulate cAMP production in the bacterium Mycobacterium tuberculosis, potentially blocking its ability to metabolize lipids and thus improving drug efficacy. Their ultimate goal is to shorten TB treatment regimens and combat drug resistance.

Dr. Joanne L. Flynn's lab focuses on improving the efficacy of vaccines against tuberculosis (TB), a major global health concern. The lab investigates new strategies to enhance the immune response to the BCG vaccine using modern techniques and animal models. Their research aims to better understand how to protect against TB and identify key markers of vaccine effectiveness.

Dr. Jeffrey D. Cirillo's lab at Texas A&M University specializes in understanding tuberculosis (TB) and improving vaccines against this disease. They study the BCG vaccine's variability in effectiveness and develop advanced imaging techniques to detect Mycobacterium tuberculosis in real-time. Through animal models and human studies, they aim to correlate immune responses with vaccine efficacy and create innovative ways to monitor TB infections and assess new treatments more quickly.

Dr. Charles A. Scanga's lab at the University of Pittsburgh focuses on improving tuberculosis (TB) vaccines, particularly for HIV-infected children. The research explores new delivery methods and vaccine strains to enhance safety and effectiveness. Using animal models, the lab aims to better understand immune responses to TB vaccines and how these can be optimized for vulnerable populations.

Dr. Mary Jo Turk's lab at Dartmouth College focuses on understanding how a specific type of immune cell, called tissue resident memory T cells, functions in fighting cancer. Their research looks at how these cells are generated, how they move within the body, and their role in preventing cancer recurrence and spread. By studying both mice and human patients, the lab aims to develop strategies to enhance tumor immunity, potentially leading to better cancer treatments.

Dr. Kevan C. Herold's lab at Yale University focuses on understanding and developing treatments for Type 1 diabetes, an autoimmune condition where the immune system attacks insulin-producing cells in the pancreas. The lab uses advanced pancreatic organoid models to investigate how different immune responses affect disease progression and treatment outcomes. They aim to uncover important cellular features that could lead to improved therapies and a better understanding of why some patients respond differently to treatments.

Dr. Jonathan N Pruneda’s lab focuses on understanding how bacteria interact with the immune system by manipulating a protein signaling system known as ubiquitin. The lab specifically investigates a less-studied form of ubiquitin signaling called Lys6 polyubiquitin, looking at how bacterial pathogens use this to evade immune responses and affect protein degradation in host cells. This research could reveal new strategies for combating bacterial infections and developing therapeutics.

Dr. Mark T. Anderson's lab at the University of Michigan focuses on understanding how a specific type of bacteria, known as uropathogenic E. coli, causes urinary tract infections (UTIs), particularly in women of different ages. The lab studies the behavior of these bacteria from the initial colonization in the urinary tract to the development of acute infections. By comparing gene expression in young and postmenopausal women, the team aims to uncover how these infections occur and identify potential target for new treatments and prevention strategies.

Dr. Chelsie Armbruster's lab focuses on understanding urinary tract infections (UTIs), particularly those associated with catheter use. They explore how certain bacteria interact with the urinary tract and the role of glycosaminoglycans, a protective layer in the bladder, in infection and immune responses. The lab aims to discover new ways to prevent these infections, especially in vulnerable populations, by studying bacterial behavior and the infection process.

Dr. Ronghua Zhuge's lab at the University of Massachusetts Medical School focuses on understanding how ion channels in uterine smooth muscle cells affect uterine contractions, which are important for reproduction. The lab studies conditions like adenomyosis, a disease that impacts many women and can cause significant distress. By exploring the roles of specific calcium channels in these muscles, the research aims to uncover new treatment strategies for gynecological disorders.

Dr. Matthias Johannes Schnell's lab focuses on developing a new vaccine against the Crimean-Congo hemorrhagic fever virus (CCHFV), a dangerous pathogen with high fatality rates. The lab uses innovative vaccine platforms based on inactivated rabies and vesicular stomatitis viruses to generate protective immunity against CCHFV. They work on understanding how these vaccines work and aim to create a safer method for vaccine testing using animal models, ultimately contributing to public health safety.